89
Views
3
CrossRef citations to date
0
Altmetric
Research Article

The effects of PPAR-γ agonist pioglitazone on anxiety and depression-like behaviors in lipopolysaccharide injected rats

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1223-1232 | Received 25 Sep 2018, Accepted 24 Sep 2019, Published online: 07 Oct 2019
 

Abstract

Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists have been suggested to have some effects of central nervous system. In the present study, the effects of PPAR-γ agonist pioglitazone (pio) on anxiety and depression-like behaviors were investigated in lipopolysaccharide (LPS) injected rats. The animal groups include (n = 10 in each): (1) control, (2) LPS (1 mg/kg, two hours before behavioral tests), (3–5) LPS + Pio 10, LPS + Pio 20, and LPS + Pio 30 groups which received 10, 20, and 30 mg/kg of pio respectively and 30 min later were injected by LPS. Pretreatment by pio improved the behaviors of the LPS injected rats in open field, elevated plus maze and forced swimming tests protected from brain tissues oxidative damage and reduced in total white blood cell (WBC). It was indicated that pio had anti-anxiety and anti-depressant effect in LPS injected rats.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The authors would like to thank National Institute for Medical Research Development (Grant No.: 958781) for its financial supports.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.